Takeda Pharmaceutical (TAK) Total Liabilities (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Total Liabilities of $50.8 billion for Q2 2026, up 3.07% year-over-year from $49.3 billion in Q2 2025, and down 1.32% quarter-over-quarter from $51.5 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Total Liabilities (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Total Liabilities history runs 9 years deep, the most recent figure standing at $50.8 billion for Q2 2026.
- In Q2 2026, Total Liabilities rose 3.07% year-over-year to $50.8 billion; the TTM figure through Jun 2026 stood at $50.8 billion (up 3.07% YoY), while the FY2026 annual figure was $53.7 billion, up 11.83% from the prior year.
- Total Liabilities for Q2 2026 stood at $50.8 billion, down from $51.5 billion in the prior quarter.
- The five-year high for Total Liabilities was $64.5 billion in Q1 2022, with the low at $47.9 billion in Q1 2025.
- The 5-year median for Total Liabilities is $51.7 billion (2022), against an average of $53.4 billion.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities declined 19.96% in 2022, then advanced 7.51% in 2026.
- Takeda Pharmaceutical's Total Liabilities stood at $51.9 billion in 2022, then declined by 2.44% to $50.6 billion in 2023, then dropped by 0.08% to $50.6 billion in 2024, then slipped by 0.22% to $50.5 billion in 2025, then climbed by 0.78% to $50.8 billion in 2026.
- Business Quant data shows TAK's Total Liabilities at $50.8 billion in Q2 2026, $51.5 billion in Q1 2026, and $50.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.12 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 2.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.85 Bn |
| Mar 31, 2026 | 51.53 Bn |
| Dec 31, 2025 | 50.45 Bn |
| Sep 30, 2025 | 49.81 Bn |
| Jun 30, 2025 | 49.33 Bn |
| Mar 31, 2025 | 47.93 Bn |
| Dec 31, 2024 | 50.57 Bn |
| Sep 30, 2024 | 51.30 Bn |
| Jun 30, 2024 | 54.14 Bn |
| Mar 31, 2024 | 52.87 Bn |
| Dec 31, 2023 | 50.61 Bn |
| Sep 30, 2023 | 54.02 Bn |
| Jun 30, 2023 | 57.43 Bn |
| Mar 31, 2023 | 57.48 Bn |
| Dec 31, 2022 | 51.87 Bn |
| Sep 30, 2022 | 57.02 Bn |
| Jun 30, 2022 | 59.91 Bn |
| Mar 31, 2022 | 64.49 Bn |
| Dec 31, 2021 | 64.81 Bn |
| Sep 30, 2021 | 65.73 Bn |